Header

Lymphoma Clinical Trials

Category:Adult
Status:Active

Displaying Trial 1 - 30 of 41 in total

Pembrolizumab After ASCT for Hodgkin Lymphoma and DLBCL

This phase II study is designed to determine the clinical efficacy of PD-1 blockade, using the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475), administered as consolidation therapy after aut...

Diagnosis: Lymphoma

Phase: 2

Protocol Number: 14-566

Study of Tipifarnib in Subjects With Relapsed or Refractory Peripheral T-Cell Lymphoma

This Phase II studyis designed to investigate the antitumor activity in terms of objective response rate (ORR) of tipifarnib in 18 subjects with advanced Peripheral T-Cell Lymphoma (PTCL). The tota...

Diagnosis: Lymphoma

Phase: 2

Protocol Number: 16-087

AT13387 in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Diffuse Large B-cell Lymphoma

This phase II trial studies how well AT13387 works in treating patients with anaplastic large cell lymphoma, mantle cell lymphoma, or diffuse large B-cell lymphoma that has not responded to previou...

Diagnosis: Lymphoma

Phase: 2

Protocol Number: 16-712

Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant

This phase II trial studies how well ibrutinib works in treating patients after a donor stem cell transplant for lymphoma that is not responding to treatment or has come back. Ibrutinib may stop th...

Diagnosis: Lymphoma

Phase: 2

Protocol Number: 17-261

Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)

The study is designed as a Phase II, multicenter trial of vaccination with Dendritic cell/myeloma fusions with granulocyte macrophage colony-stimulating factor (GM-CSF) adjuvant plus lenalidomide m...

Diagnosis: Multiple Myeloma, Lymphoma

Phase: 2

Protocol Number: 16-113

Safety Study of Anti-LAG-3 in Relapsed or Refractory Hematologic Malignancies

The purpose of this study is to characterize the safety, tolerability and maximum tolerated dose of BMS-986016 administered alone or in combination with Nivolumab to subjects with relapsed hematolo...

Diagnosis: Lymphoma

Phase: 1

Protocol Number:

A Phase 1 Study to Investigate the Safety and Tolerability of REGN1979 in Patients With CD20+ B-Cell Malignancies

This is an open-label, multi-center, dose escalation study of REGN1979 administered as an IV (intravenous) infusion. This phase 1 study will investigate the safety and tolerability of REGN1979 in p...

Diagnosis: Lymphoma

Phase: 1

Protocol Number: 15-212

ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas

This study evaluates the anti-tumor effects of ALRN-6924 in patients with advanced solid tumors or lymphomas with WT TP53.

Diagnosis: Lymphoma, Solid Tumor/Phase I

Phase: 1

Protocol Number:

A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma

This is a Phase 1 dose exploration study of LAM-002A administered by mouth in patients with relapsed or refractory B-cell NHL. Safety, tolerability, pharmacokinetics (PK) and preliminary activity w...

Diagnosis: Lymphoma

Phase: 1

Protocol Number: 15-421

Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (NHL)

This open-label Phase 1 study will evaluate the safety, PK, and antitumor activity of modified T cells (JCAR017) administered to adult patients with relapsed or refractory B-cell NHL. The dose and ...

Diagnosis: Lymphoma

Phase: 1

Protocol Number: 15-404

A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed Lymphoma

The goal of the study is to identify a dose and schedule of CC-486 that can be safely administered with R-CHOP. To evaluate the safety and maximum tolerated dose (MTD) or the maximal administered d...

Diagnosis: Lymphoma

Phase: 1

Protocol Number: 15-229

Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer

The overarching objective of the study is to determine the effectiveness of LMWH/ warfarin vs. DOAC anticoagulation for preventing recurrent VTE in cancer patients. The intervention strategy is Dir...

Diagnosis: Solid Tumor/Phase I, Multiple Myeloma, Lymphoma

Phase:

Protocol Number: 16-406

Study of the Safety and Efficacy of MIW815 (ADU-S100) in Patients With Advanced/Metastatic Solid Tumors or Lymphomas

The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics and antitumor activity of MIW815 (ADU-S100) administered via intratumoral injection.

Diagnosis: Solid Tumor/Phase I, Lymphoma

Phase:

Protocol Number: 16-274

A Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Relapsed/Refractory Primary Testicular Lymphoma (PTL)

The purpose of this study is to determine whether Nivolumab is effective in the treatment of Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Relapsed/Refractory Primary Test...

Diagnosis: Lymphoma

Phase:

Protocol Number: 16-340

Study of Allogeneic EBV-CTLs in EBV-Associated Viremia or Malignancies

This is a multicenter expanded access protocol to provide human leukocyte antigen (HLA) partially-matched third-party allogeneic EBV-CTLs for the treatment of EBV-associated viremia and disease for...

Diagnosis: Lymphoma

Phase:

Protocol Number: 16-535

A Phase II Study of Venetoclax in Combination With Dose-adjusted EPOCH-R for Patients With Richter's Syndrome

This research study is evaluating the combination of a study drug, venetoclax, and a standard chemotherapy regimen, EPOCH-R, as a possible treatment for Richter's Syndrome. The drugs involved ...

Diagnosis: Lymphoma

Phase:

Protocol Number: 16-596

Safety, PK, PD, and Antitumor Activity of SNS-062 in B Lymphoid Cancers

Phase 1b (Dose Escalation) in primarily CLL/SLL patients will evaluate safety and pharmacology of self-administered twice a day oral doses beginning at 25 mg/dose for 4 weeks with succeeding cohort...

Diagnosis: Lymphoma

Phase:

Protocol Number: 17-139

Promoting Resiliency Among Lymphoma Survivors: The 3RP-Lymphoma

The Relaxation Response Resiliency Program (3RP) was developed by researchers at the MGH Benson-Henry Institute for Mind Body Medicine; This program has recently been adapted to target the needs of...

Diagnosis: Lymphoma

Phase:

Protocol Number: 17-063

Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas

This is a phase I, open label, single-arm, multi-center, dose-finding study of venetoclax in combination with DA-EPOCH-R in patients with aggressive B-Cell Lymphomas.

Diagnosis: Lymphoma

Phase:

Protocol Number: 17-078

Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies

This is a study to test how safe the combination of the drugs Romidepsin and Pralatrexate are in patients with lymphoid malignancies and to determine the dose of the combination of drugs that is sa...

Diagnosis: Lymphoma

Phase:

Protocol Number: 16-615

Dose Escalation Study of mRNA 2416 for Intratumoral Injection to Patients With Advanced Malignancies

This clinical study will assess the safety and tolerability of escalating intratumoral doses of mRNA 2416 in patients with relapsed/refractory solid tumor malignancies or lymphoma

Diagnosis: Solid Tumor/Phase I, Lymphoma

Phase:

Protocol Number: 17-334

A Phase 2 Study of Pembrolizumab in Patients With Histiocyte/Dendritic Cell Neoplasms and Biologically Selected Subtypes of Relapsed/Refractory Aggressive Lymphomas

This research study is studying a drug called pembrolizumab as a possible treatment for aggressive lymphoma or a histiocyte or dendritic cell neoplasm. The drug involved in this study is: -Pembroli...

Diagnosis: Lymphoma

Phase:

Protocol Number: 17-448

A Phase 2 Multicenter Study Evaluating Subjects With Relapsed/Refractory Mantle Cell Lymphoma

Study KTE-C19-102 is a phase 2, multicenter, open-label study evaluating the efficacy of KTE-C19 in subjects with Relapsed/Refractory MCL

Diagnosis: Lymphoma

Phase:

Protocol Number: 16-134

Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory CLL or SLL (TRANSCEND-CLL-004)

This is a Phase 1/2, open-label, multicenter study to determine the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory CLL or SLL. The study will include a Phase 1 part to...

Diagnosis: Leukemia/MDS, Lymphoma

Phase:

Protocol Number: 17-545

A Study Evaluating the Efficacy of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma

The purpose of this study is to evaluate whether axicabtagene ciloleucel therapy improves the clinical outcome compared with standard of care second-line therapy in patients with relapsed/refractor...

Diagnosis: Lymphoma

Phase:

Protocol Number: 17-541

Trial of Hu5F9-G4 in Combination With Rituximab in Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

This Phase 1b/2 trial will evaluate Hu5F9-G4 in combination with rituximab. Hu5F9-G4 is a monoclonal antibody which is designed to block a protein called CD47, which is widely expressed on human ca...

Diagnosis: Lymphoma

Phase:

Protocol Number: 17-313

Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma

The purpose of this study is to test any good and bad effects of the study drug called ruxolitinib. Ruxolitinib works by blocking a protein called JAK. JAK works along with another protein called S...

Diagnosis: Lymphoma

Phase:

Protocol Number: 17-548

A Study Comparing BGB-3111 With Bendamustine Plus Rituximab in Patients With Previously Untreated CLL or SLL

This study will enroll subjects with previously untreated CLL/SLL into two cohorts (Cohort 1 without del[17p] and Cohort 2 with del[17p]). Cohort 1 subjects will receive either "BGB-3111 alone...

Diagnosis: Lymphoma

Phase:

Protocol Number: 17-544

A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies (PLATFORM)

This is an open-label, multi-arm, multi-cohort, multi-center, Phase 1/2 study to determine the safety, tolerability, PK, efficacy and patient reported quality of life of JCAR017 in combination with...

Diagnosis: Lymphoma

Phase:

Protocol Number: 17-585

Study of AZD5991 in Relapsed or Refractory Haematologic Malignancies.

This study is a multicenter, open-label, nonrandomized, sequential group, dose-escalation study to assess safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of ascending dos...

Diagnosis: Lymphoma

Phase:

Protocol Number: 17-558

<< Previous 1
'